Last reviewed · How we verify

Hiltonol and autologous dendritic cells

Clinica Universidad de Navarra, Universidad de Navarra · Phase 2 active Biologic

Hiltonol and autologous dendritic cells is a Biologic drug developed by Clinica Universidad de Navarra, Universidad de Navarra. It is currently in Phase 2 development.

At a glance

Generic nameHiltonol and autologous dendritic cells
SponsorClinica Universidad de Navarra, Universidad de Navarra
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hiltonol and autologous dendritic cells

What is Hiltonol and autologous dendritic cells?

Hiltonol and autologous dendritic cells is a Biologic drug developed by Clinica Universidad de Navarra, Universidad de Navarra.

Who makes Hiltonol and autologous dendritic cells?

Hiltonol and autologous dendritic cells is developed by Clinica Universidad de Navarra, Universidad de Navarra (see full Clinica Universidad de Navarra, Universidad de Navarra pipeline at /company/clinica-universidad-de-navarra-universidad-de-navarra).

What development phase is Hiltonol and autologous dendritic cells in?

Hiltonol and autologous dendritic cells is in Phase 2.

Related